Melqart Asset Management (UK) Ltd - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 157 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 2.78 and the average weighting 0.2%.

Quarter-by-quarter ownership
Melqart Asset Management (UK) Ltd ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2018$16,932,000
-48.3%
134,000
-65.7%
1.58%
-43.5%
Q2 2018$32,775,000
+78.7%
390,600
+31.0%
2.80%
+26.9%
Q1 2018$18,345,000
+39.6%
298,200
+32.5%
2.20%
+3.6%
Q4 2017$13,145,000225,0002.13%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q3 2023
NameSharesValueWeighting ↓
Samsara BioCapital, LLC 640,688$14,787,0002.73%
DeepCurrents Investment Group LLC 416,800$9,620,0000.33%
DUALITY ADVISERS, LP 105,668$2,439,0000.21%
EULAV Asset Management 335,000$7,732,0000.21%
Virtus ETF Advisers LLC 19,375$447,0000.19%
Hennion & Walsh Asset Management, Inc. 135,214$3,121,0000.19%
PDT Partners, LLC 110,592$2,552,0000.18%
KETTLE HILL CAPITAL MANAGEMENT, LLC 70,256$1,622,0000.16%
ALTRINSIC GLOBAL ADVISORS LLC 168,800$3,896,0000.12%
WOODWARD DIVERSIFIED CAPITAL, LLC 8,939$206,0000.12%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders